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Multi-Site N-glycan mapping study 1: Capillary
electrophoresis – laser induced fluorescence
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An international team that included 20 independent laboratories from biopharmaceutical companies, universities,
analytical contract laboratories and national authorities in the United States, Europe and Asia was formed to evaluate
the reproducibility of sample preparation and analysis of N-glycans using capillary electrophoresis of 8-aminopyrene-
1,3,6-trisulfonic acid (APTS)-labeled glycans with laser induced fluorescence (CE-LIF) detection (16 sites) and ultra high-
performance liquid chromatography (UHPLC, 12 sites; results to be reported in a subsequent publication). All
participants used the same lot of chemicals, samples, reagents, and columns/capillaries to run their assays. Migration
time, peak area and peak area percent values were determined for all peaks with >0.1% peak area. Our results
demonstrated low variability and high reproducibility, both, within any given site as well across all sites, which indicates
that a standard N-glycan analysis platform appropriate for general use (clone selection, process development, lot
release, etc.) within the industry can be established.
Introduction
Recent rapid expansion in the field of biopharmaceutical product
development and the concomitant commercialization of therapeutic
proteins has increased the need to implement rapid and reproducible
analytical methods for monitoring important post-translational
modifications of the product, such as N-glycosylation. Regulatory
agencies consider N-glycosylation to be a critical quality attribute
due to the potential effects on pharmacokinetics, biological activity,
stability and immunogenicity.1 Product quality attribute evaluation
in the biopharmaceutical industry often requires the use of comple-
mentary analytical methodologies (e.g., capillary electrophoresis, liq-
uid chromatography) to alleviate the risks associated with using only
one analytical tool.2 Additionally, applying orthogonal separation
techniques can help provide more consistent and more thorough
characterization of lots. In the past few years, capillary
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electrophoresis with laser-induced fluorescent detection (CE-LIF)
has become an important bioanalytical tool in the biotechnology
and biopharmaceutical industries to provide comprehensive
glycosylation analysis data. 3 In CE-LIF-based glycan analysis, neu-
trally coated capillaries are used for the separation of fluorophore
labeled (8-aminopyrene-trisulfonic acid, APTS) carbohydrate mole-
cules. CE provides a directly orthogonal approach to liquid chroma-
tography and mass spectrometry, and therefore its use addresses
requests from regulatory agencies for orthogonality in product
characterization.
During the various steps of the development process, CE can
provide identification and relative quantitation of glycans in a
rapid or high throughput manner with high sensitivity. This allows
fast turnaround times for glycan analysis and the ability to monitor
product consistency, as well as potentially immunogenic glycan
epitopes. There are, however, some limitations, as co-migration of
some glycans may occur. In the method presented here, one glycan
of interest (Man5) is observed to co-migrate with another glycan.
This can be addressed using the same approach as one would use
in chromatography; exoglycosidase treatment to remove the co-
migrating species would allow quantitation of the Man5 glycan.
Additionally, the use of various exoglycosidases can help provide
the elucidation of other glycan structures. Glycan analysis by CE
can also be utilized in a GMP environment to provide results for
comparability analysis and product release.
To prove the reproducibility and transferability across sites of
CE-LIF as a routine analytical methodology for N-glycan analysis of
biopharmaceuticals, an intercompany collaboration3-5 (initially
formed at the CASSS CE Pharm 2012 meeting) was formed with
16 laboratories located in North America, Europe and Asia from
independent industrial and academic participants. This endeavor
assessed intra- and inter-laboratory repeatability and reproducibility
(different laboratories, different personnel, multiple instruments and
different days of analysis) of the selected sample preparation6 and
CE-LIF method used. A labeled glycan standard ready for analysis
and a glycoprotein were chosen as test articles to assess the contribu-
tion to variability of the analysis alone vs. that of the sample prepara-
tion and analysis. After a predefined system suitability test to assure
that systems were performing optimally, the laboratories analyzed 6
different samples including a pre-labeled homo-oligomer ladder
standard, 3 pre-labeled glycan standards (containing only high man-
nose and complex type afucosylated and fucosylated glycans),
released and pre-labeled glycan test article sample and 3 parallel-pre-
pared glycoprotein test articles. Statistical analysis of the obtained
results was performed following ISO 5725–2 guideline principles.7
Glucose Unit (GU) values were determined2,8 for all peaks and the
data provided by each laboratory was critically evaluated to identify
outliers.
The goal of this interlaboratory study was, after agreement
among the participants, to use the most advanced procedures and
methods currently available to evaluate comparability of results
across sites in order to expedite regulatory and industrial recogni-
tion of CE-LIF methods as a reliable toolset to comprehensively
characterize the N-glycosylation patterns of therapeutic proteins.
To this end, calibration procedures and best practices, detailed
protocols and a 2-hour training webinar were provided by the
respective suppliers to ensure that participants understood the
procedures. The results of the system suitability injections were
evaluated to assure that all instruments were calibrated and run-
ning properly.
Results
A schematic representation of the sample preparation work-
flow is shown in Figure 1. The samples were first denatured and
loaded onto the cartridges for digestion. The released glycans
were then isolated, dried and labeled with APTS via reductive
amination. The labeled glycans were cleaned up from excess
labeling reagents and analyzed by CE-LIF. Table 1 provides data
for inter-laboratory reproducibility for relative peak areas, includ-
ing all participating laboratories. The means for each peak from
each site are presented along with the overall means. The %RSD
represent the overall inter-laboratory reproducibility and is dis-
played as a heatmap, with green being low and red being high.
Figure 2 depicts the CE-LIF traces of the APTS-labeled parti-
tioned N-glycan libraries (APTS-labeled glycan libraries are com-
mercially available products; see supplemental section for
information). The upper trace shows the analysis of the high-
mannose glycans featuring excellent separation of the positional
mannose isomers of M7 and M8 structures. The middle trace
displays the separation of afucosylated biantennary sugars. The
lower trace shows the analysis of the fucosyl biantennary library;
co-migration of G1F[3] and G1F[6]B is observed in peak 27.
Based on the comparison of the 3 traces, one can predict that
some of the peaks have the tendency to co-migrate when a full
mixture of the glycan species represented by the partitioned
libraries are present.
Figure 3 displays the CE-LIF N-glycan profile of the Protein
Test Article showing 20 peaks from the mixture of 27 identified
Figure 1. Schematic representation of the overall strategy for N-glycan
analysis of the Protein Test Article using CE-LIF. 1) Peptide N-glycosidase
F-mediated release of N-linked carbohydrates was followed by 2) a rapid
reductive amination-based labeling reaction with APTS. 3) In the next
step, salts and unbound dye molecules are removed from the sample
and the APTS derivatized glycans are eluted by HPLC-grade water. 4)
Finally, the samples are analyzed by CE-LIF.
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structures. The sample was spiked with 8% high-mannose-type
glycans (M5-M9); therefore, some of those glycans co-migrated
with certain complex structures and appear as either tailing or
fronting peaks. This type of electrophoretic profile was consis-
tently obtained by all laboratories.
Quantitative Analysis of
the Protein Test Article
All electropherograms were
integrated by the study coordina-
tors using the same integration
parameters. Migration times,
absolute, relative and total peak
area values were determined for
the 20 peaks found in the Protein
Test Article N-glycan profiles
(Fig. 3). Glycan structures were
assigned based on the Partitioned
N-Linked Glycan Libraries.
Statistical analysis was per-
formed to assess intra-laboratory
repeatability for absolute, relative
and total peak areas; this was per-
formed for each of the participat-
ing laboratories. The results from
a randomly selected site, site F,
are presented in Figure 4. The
results obtained at site F show
very low variability in the results,
highlighting the precision of the
method. The corresponding results for the remaining sites are
contained in the Supplemental Data section; most of the remain-
ing sites showed similar results. Inter-laboratory reproducibility
(for all participating laboratories) for relative peak areas was also
assessed (Table 1). The results compiled from all the sites
Table 1. Inter-laboratory reproducibility for relative peak areas, including all participating laboratories. An elevated %RSD is observed for some peaks due to
the inclusion of results from outlying sites.
Mean of replicate injections by site
Peak # Name (UOXF) A B D E F G H I J K L M N O P S Overall Mean %RSD
1 A2G2S2 0.07 0.13 0.11 0.13 0.12 0.11 0.14 0.12 0.10 0.12 0.12 0.12 0.12 0.12 0.13 0.13 0.12 13.68%
2 FA2G2S2 0.64 0.76 0.71 0.77 0.71 0.73 0.74 0.72 0.70 0.76 0.74 0.72 0.79 0.72 0.77 0.77 0.73 5.08%
3 FA2BG2S2 0.55 0.63 0.57 0.63 0.62 0.61 0.61 0.60 0.61 0.62 0.62 0.59 0.66 0.60 0.64 0.65 0.61 4.81%
4 FA2[6]G1S1 0.20 0.21 0.20 0.21 0.22 0.22 0.21 0.22 0.21 0.21 0.24 0.20 0.22 0.22 0.21 0.20 0.21 4.56%
5 FA2[3]G1S1 1.69 1.68 1.65 1.70 1.69 1.69 1.70 1.65 1.68 1.70 1.66 1.68 1.71 1.65 1.69 1.68 1.68 1.11%
6 A2G2S1 0.39 0.52 0.49 0.49 0.48 0.50 0.53 0.52 0.47 0.52 0.50 0.57 0.50 0.52 0.50 0.57 0.51 8.14%
7 A1 0.12 0.18 0.16 0.14 0.15 0.18 0.18 0.18 0.15 0.18 0.17 0.17 0.18 0.18 0.17 0.22 0.17 13.34%
8 FA2G2S1CA2 8.09 8.67 8.39 8.69 8.37 8.69 8.69 8.47 8.49 8.67 8.68 8.70 8.70 8.46 8.62 8.63 8.56 2.01%
9 FA2BG2S1CM5 2.78 2.47 2.42 2.42 2.61 2.38 2.41 2.54 2.28 2.45 2.47 2.59 2.53 2.54 2.45 2.74 2.51 5.16%
10 Unknown 1 0.36 0.25 0.23 0.23 0.26 0.26 0.25 0.26 0.28 0.26 0.24 0.32 0.26 0.26 0.26 0.29 0.27 12.12%
11 A2B 0.09 0.15 0.12 0.12 0.11 0.14 0.13 0.16 0.10 0.14 0.38 0.12 0.12 0.16 0.12 0.14 0.15 46.29%
12 FA2CM6CA2[6]G1 21.01 20.77 21.26 20.93 20.80 20.74 20.74 20.75 20.83 20.82 20.52 20.64 20.69 20.74 20.74 20.53 20.78 0.86%
13 A2[3]G1 0.25 0.33 0.31 0.28 0.32 0.31 0.32 0.35 0.28 0.32 0.30 0.31 0.30 0.36 0.30 0.35 0.31 8.79%
14 FA2B 2.94 3.00 2.97 2.96 2.93 2.98 2.98 2.98 2.96 3.00 3.36 2.83 2.94 2.98 2.97 2.96 2.98 3.63%
15 FA2[6]G1CM7 23.05 22.73 23.02 23.00 22.86 22.88 22.81 22.91 23.01 22.81 22.55 22.48 22.74 22.90 22.89 22.41 22.82 0.84%
16 FA2[3]G1CA2G2CFA2B[6]G1 14.19 14.01 14.09 13.87 14.12 14.05 14.03 14.05 14.11 13.99 13.79 14.18 13.96 14.05 14.06 14.02 14.04 0.72%
17 M8CFA2B[3]G1 1.95 2.17 2.09 2.12 2.05 2.03 2.12 2.19 2.00 2.11 2.54 2.12 2.17 2.20 2.00 2.31 2.14 6.65%
18 FA2G2CM9 19.94 19.76 19.69 19.75 19.97 19.88 19.85 19.76 20.16 19.73 19.55 19.97 19.84 19.75 19.89 19.77 19.83 0.72%
19 FA2BG2 1.56 1.45 1.41 1.42 1.48 1.48 1.44 1.45 1.46 1.45 1.42 1.56 1.45 1.45 1.47 1.50 1.47 2.94%
20 Unknown 2 0.12 0.13 0.12 0.13 0.14 0.13 0.13 0.13 0.12 0.12 0.13 0.13 0.14 0.13 0.13 0.13 0.13 4.03%
Figure 2. CE-LIF analysis of APTS-labeled partitioned N-glycan libraries of high-mannose (upper trace), fucosyl
biantennary (lower trace) and afucosyl biantennary (middle trace) structures. All identified N-glycan structures
are listed in the right panel with their Oxford notation.9 Commonly used names (highlighted by red in brack-
ets) are also given for structures that can usually be found on therapeutic antibodies.
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revealed some differences in quantitation at some sites, which
resulted in an elevated %RSD for some peaks. Outlier analysis
would confirm that some sites were of high variance from the
mean.
The procedure described in the ISO 5725–2 for outlier
removal was applied based on migration time and %Area, sepa-
rately, for each of the 20 peaks across all sites. First, a visual eval-
uation for consistency of the results and laboratories was
performed by using the Mandel’s k and h statistics. The
Cochran’s and Grubb’s tests were then applied to reject data in
individual or outlier laboratories, respectively. There were 2 pos-
sible types of outliers: (1) outlying results for each of the peaks
within the individual laboratories, meaning that the data was too
low or too high compared to the other results; and (2) outlying
laboratories that deviate either in precision or in mean values
compared to the other laboratories. The statistic k measured the
intra-laboratory consistency by comparing the standard deviation
of the percent peak area values for a selected peak within one lab-
oratory to the mean standard deviation of the different laborato-
ries for that same peak. The homogeneity of the variances was
then tested with the Cochran’s test.
As an example, Figure 5 displays the results of the Grubb’s
test for the average %Area values of peak 15 by sites and repli-
cates. In this case 2 outlying values (red columns) were identified
and should be removed from the data set. Figure 6 shows the
result of outlier analysis for relative peak areas by sites and peaks.
If any laboratory had more than
5 peaks in its Protein Test Article
profiles, which were deviating
either in precision or mean values
compared to other laboratories,
all of its data was eliminated from
the data set and outlier analysis
was repeated on the reduced data
set. Since site A obtained deviat-
ing %Area values for more than
half of the peaks in all Protein
Test Article replicates, its data
were not used in the calculation
of the final results; migration
time values obtained from site A
were also outliers for most peaks.
This indicated that either sample
preparation or the separation
conditions were different in this
laboratory. A subsequent investi-
gation found that the separation
temperature used by site A was
25C instead of 20C, as defined
in the study protocol. Due to the
higher separation temperature,
the viscosity of the separation
buffer decreased, which resulted
in shorter migration times.
Decreased viscosity of the separa-
tion media affected the peak
shapes, and affected resolution of the injected sample. Since most
of the integration parameters were fixed during the data evalua-
tion, this decrease in resolution and change in peak shape resulted
in deviating %Area values for more than half of the integrated
peaks in the profile.
After the outlier analysis was completed, the results obtained
from 3 separate injections of the replicate runs were taken and
migration time means were calculated for each peak of the repli-
cates. All integrated peaks in the Protein Test Article profiles
were then calibrated against the mean of 2 APTS-labeled malto-
dextrin ladder runs, and assigned glucose-unit values by fitting a
fifth-order polynomial distribution curve to generate GUCE val-
ues. Glucose-unit values were calculated from the migration-time
means of certain peaks based on 3 parallel injections and from
the migration-time means of the 2 glucose homo-oligomer ladder
runs, which were injected prior to and after the actual Protein
Test Article. Analyses of the pre-labeled ladder standard were
very reproducible across the sites (Table 2). Both migration
times and %Area of the ladder peaks (only data for the G2 peak
presented) were generally very stable between injections; means
were calculated from the 6 injections performed at each site.
Finally, repeatability, variation in the results of within a labora-
tory, and reproducibility, variation in the results between the labora-
tories, were determined for both migration times and %Peak area by
peaks. Table 3 summarizes the overall mean, the repeatability, and
reproducibility of each peak. In Table 3, Panel A contains the
Figure 3. CE-LIF analysis trace of the APTS-labeled N-glycan profile of the Protein Test Article. The 20 most-
abundant peaks were integrated in all the submitted profiles and their migration times and relative and total
areas were then used to determine internal precision and reproducibility of the N-glycan mapping assay. The
right panel shows the corresponding GUCE values for all integrated peaks in their migration order, as well as
the name of all identified structures using Oxford notation.9
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calculated mean %Area values and
their relative standard deviation
means for all the 20 peaks larger than
0.1%; Panel A is divided into 3 parts.
The upper part contains peaks with
relative area between 0.1% and 1%.
The mean repeatability for these
low-abundance structures was
1.53%, while the mean reproducibil-
ity across the laboratories was
7.30%. The middle part contains
peaks with relative area between 1%
and 10%; the mean reproducibility
across the laboratories for these peaks
was 2.63%. The four major peaks
(relative areas >10%) had a mean
repeatability and reproducibility
0.30% and 0.80%, respectively
(lower section of panel A). The gen-
eral means of repeatability and repro-
ducibility for %Area were 0.95%
and 4.60%, respectively. Panel B in
Table 3 shows the overall mean of
the migration times by peak. The
mean repeatability and reproduc-
ibility of migration time were
0.06% and 2.24%, respectively.
These results demonstrate that the
study assay was robust and highly
reproducible, which affirms its usefulness in the biopharmaceu-
tical industry. Additionally, the observed reproducibility indi-
cates the potential to validate the method presented for the
relative quantitation of glycans. A 20% CV for peaks between
0.1 and 1.0% would be suggested as this would comply with
industry guidelines and standards to ensure accurate analysis.
Accurate glycan analysis can
allow for the determination of
relevant indices (e.g., fucosyla-
tion, galactosylation mannosyla-
tion, sialylation), which can be
used to predict biological effects
(e.g., pharmacokinetics/pharma-
codynamics, antibody-dependent
cell-mediated cytotoxicity, com-
plement-mediated cytotoxicity).
Discussion
Inter-laboratory studies fulfill
several requirements of the qual-
ity management of bioanalytical
measurements. They contribute
to the validation of analytical
methods, assess the proficiency of
individual laboratories, estimate
measurement uncertainty and certify test articles in a wide range
of application and fields. The glycosylation profiles and quanti-
tated values of the study’s test articles were consistent for all
organizations involved in the study. This study has shown that
the applied CE-LIF method for the analysis of glycans provides
reliable intra- and inter-laboratory results across laboratories in
Figure 5. Grubb’s test for %Area of peak 15 in the Protein Test Article by sites and replicates. Red columns rep-
resent those replicate samples of site S where the %Area value of peak 15 were considered.
Figure 4. Statistical analysis of site F. Three chemical replicates were prepared; 3 injections were performed
for each replicate. (A) Relative peak area for each integrated peak. (B) Absolute peak areas for each inte-
grated peak. (C) Total peak area of each replicate.
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North America, Europe and Asia, and it is therefore a robust tool
for N-glycan analysis that can confidently be applied on its own
or as an orthogonal/complementary technique to other existing
methods.
It is anticipated that this kit-based sample preparation com-
bined with CE-LIF analysis will help to expedite pharmaceutical
processes in all areas of the bio-
pharmaceutical industry, and that
the results presented in this study
will highlight the applicability and
utility of capillary electrophoresis
as a bioanalytical tool.
Materials and Methods
Chemicals and reagents
Various reagents, consumables
and all samples were provided by
ProZyme Inc. (Hayward, CA,
USA) and SCIEX (previously
Beckman Coulter, Brea, CA,
USA). All capillary columns,
reagents, consumables and sam-
ples, which were sent to the partic-
ipating laboratories, were from the
same production batches. The
Protein Test Article was a mixture
of human IgG and a small amount
of bovine RNase B (the glycan
components were identified by
mass spectrometry prior to distribution). A complete list of sam-
ples, reagents and other materials used (including product and
lot numbers) can be found in the Supplemental Information
section.
Sample preparation
All glycan standards, glycan libraries and the glycan test article
were provided to each site as pre-labeled, purified (i.e., dye free)
dry aliquots; the Protein Test Article was provided to each site as
individual samples from the same production batch. Each inde-
pendent laboratory performed sample preparation using
ProZyme’s GlykoPrep Rapid N-Glycan Preparation for glycan
release, derivatization with APTS and clean up. Protein Test Arti-
cle samples were prepared in triplicate; the detailed sample prepa-
ration protocol is outlined in the Supplemental Information
section. Standards and control samples were kept at ¡20 C
when not in use and were allowed to equilibrate to room temper-
ature and vortexed prior to CE analysis.
Capillary electrophoresis
Capillary electrophoresis analyses of the APTS-labeled N-gly-
cans were performed in a PA 800 plus Pharmaceutical Analysis
System (SCIEX Brea, CA) equipped with a fluorescence detector
(excitation 488 nm, emission 520 nm, acquisition rate: 4 Hz).
The separations were accomplished using 60 cm N-CHO coated
capillaries (50-cm effective length; 50 mm i.d.) filled with the N-
CHO Carbohydrate Separation Gel Buffer (SCIEX The capillar-
ies were rinsed with the separation gel-buffer for 3 min at 30 psi
before each run. The applied electric field strength was 500 V/
cm, with the cathode at the injection side and the anode at
the detection side (reversed polarity). All separations were
Figure 6. Identification of outlying relative %Area values for all sites and peaks. Peaks are listed in their
migration order. If a site had more than 5 outlier values in its data set, the results obtained from that site
were removed from the data set and were not used in further calculations. Since site A obtained outlying
%Area values (highlighted by blue) for 12 peaks its data were rejected and were not used during the final
calculation of assay repeatability and reproducibility.
Table 2. Reproducibility of the G2 (maltose) peak of the pre-labeled malto-
oligomer ladder by sites. The table contains the mean values obtained from
summarizing up 6 consecutive injections carried out by each site. No outlier
analysis was performed on the data set before calculating the overall
means. (USP: United States Pharmacopeial Convention)
Reproducibility of the G2 (maltose) peak by sites
Site
Migration
time
Theoretical Plates
(USP)
Resolution
(USP)
Area
%
B 7.85 423551.67 30.47 1.50
D 7.46 452146.00 31.76 1.67
E 7.78 412878.00 29.90 1.60
F 7.59 369468.00 30.95 1.46
G 7.64 404761.00 29.77 1.51
H 7.94 417004.83 30.38 1.77
I 7.72 414227.17 29.41 1.56
J 7.95 426155.50 31.02 1.61
K 7.94 429485.17 30.65 1.60
L 7.85 423551.67 30.47 1.50
M 7.92 419358.50 30.42 1.33
N 7.84 419616.83 30.44 1.53
O 7.69 411039.17 29.62 1.55
P 7.63 411859.33 29.79 1.48
S 7.97 433776.33 31.08 1.68
Mean 7.78 417925.28 30.41 1.56
SD 0.16 17601.80 0.64 0.11
%RSD 2.01 4.21 2.09 6.86
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accomplished at 20C. Samples were stored at 10 C and
injected by pressure: 2 psi (13.8 kPa) for 10 sec. The software
package, 32Karat version 9.0 (SCIEX was used for data acquisi-
tion and analysis).
System certification test
As the first step, each laboratory had to perform a test anal-
ysis running the exact same test sequence including pre-labeled
standards and glycan test article samples. After completing the
analysis, the obtained data were submitted to the study coordi-
nators for data evaluation. The system certification test
guaranteed that laser powers and detector sensitivities were
within a predefined range, all units were suitable for the analy-
sis and also ensured that all obtained and submitted glycan
profiles would be comparable during the study. Detailed
descriptions of the CE system certification test, criteria and
the injection sequence are listed in the Supplemental Informa-
tion section.
Table 3. Summary of %Area, migration time repeatability and reproducibility values obtained from the Multi-Site N-Glycan study. (A) Summary of the over-
all mean %Area values for the 20 most-abundant peaks and their repeatability and reproducibility. (B) Summary of the calculated general mean migration
times and their reproducibility and repeatability by peaks.
%Area Peak #
Name
(UOXF) %Area
Repeatability
(%RSD)
Reproducibility
(%RSD)
Mean Reproducibility
(%RSD)
<1% 1 A2G2S2 0.12 1.22% 8.63% 7.30%
11 A2B 0.12 3.16% 15.46%
20 Unknown 2 0.13 2.16% 3.63%
7 A1 0.17 2.26% 9.80%
4 FA2[6]G1S1 0.21 1.43% 3.46%
10 Unknown 1 0.26 1.93% 9.45%
13 A2[3]G1 0.32 1.60% 7.22%
6 A2G2S1 0.51 0.41% 5.78%
3 FA2BG2S2 0.62 0.54% 4.95%
2 FA2G2S2 0.74 0.62% 4.58%
<10% 19 FA2BG2 1.46 0.32% 2.37% 2.63%
5 FA2[3]G1S1 1.69 0.29% 0.94%
17 M8 C FA2B[3]G1 2.11 0.51% 4.54%
9 FA2BG2S1CM5 2.50 0.71% 4.96%
14 FA2B 2.96 0.36% 1.44%
8 FA2G2S1CA2 8.59 0.28% 1.54%
>10% 16 FA2[3]G1CA2G2CFA2B[6]G1 14.10 0.76% 1.12% 0.80%
18 FA2G2CM9 19.81 0.16% 0.62%
12 FA2CM6CA2[6]G1 20.77 0.15% 0.68%
15 FA2[S]G1CM7 22.84 0.12% 0.77%
Mean 0.95% 4.60%
B
Peak
#
Name
(UOXF)
Mean Migration
Time (min)
Repeatability
(%RSD)
Reproducibility
(%RSD) Mean GUCE
Reproducibility for
GUCE (%RSD)
1 A2G2S2 11.41 0.06% 2.41% 5.47 0.21%
2 FA2G2S2 11.67 0.06% 2.38% 5.76 0.18%
3 FA2BG2S2 11.76 0.05% 2.37% 5.86 0.18%
4 FA2[6]G1S1 12.52 0.05% 2.33% 6.75 0.14%
5 FA2[3]G1S1 12.61 0.06% 2.32% 6.86 0.13%
6 A2G2S1 12.77 0.05% 2.30% 7.05 0.13%
7 A1 12.98 0.06% 2.29% 7.31 0.12%
8 FA2G2S1CA2 13.18 0.06% 2.27% 7.56 0.12%
9 FA2BG2S1CM5 13.30 0.06% 2.32% 7.72 0.12%
10 Unknown 1 13.37 0.06% 2.24% 7.80 0.21%
11 A2B 13.61 0.06% 2.23% 8.12 0.09%
12 FA2CM6CA2[6]G1 13.97 0.06% 2.24% 8.60 0.10%
13 A2[3]G1 14.25 0.05% 2.21% 8.96 0.09%
14 FA2B 14.36 0.05% 2.20% 9.10 0.08%
15 FA2[S]G1CM7 14.77 0.06% 2.17% 9.65 0.09%
16 FA2[3]G1CA2G2CFA2B[6]G1 15.01 0.06% 2.15% 9.98 0.09%
17 M8 C FA2B[3]G1 15.36 0.06% 2.13% 10.46 0.09%
18 FA2G2CM9 15.79 0.06% 2.09% 11.04 0.12%
19 FA2BG2 16.05 0.06% 2.06% 11.39 0.12%
20 Unknown 2 16.32 0.06% 2.04% 11.76 0.14%
Mean 0.06% 2.24% 0.13%
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Study design
The goal of the study was to evaluate the variability of N-gly-
can analysis across multiple sites using a standardized CE-LIF
method, adhering to our rigorous performance criteria. All peaks
with 0 .1% peak area were evaluated; outlier analysis was per-
formed using Grubb’s and Cochran’s C tests.
Study components (glycan and glycoprotein test articles and sam-
ple preparation kits provided by ProZyme; N-CHO capillaries,
N-CHO separation buffer, conditioning and separationmethod pro-
vided by SCIEX were sent out to each of the laboratories. Samples
were prepared in triplicate and each replicate was injected 3 times in
a pre-defined sequence (see Supplemental Information section). The
raw data files were then submitted to the study coordinators. Peak
areas, relative peak areas and migration times were evaluated using
the same integration parameters; GUCE values were also determined
for all peaks. After the data was evaluated, statistical and outlier analy-
ses were performed (see paragraph below); outliers were removed
from the data set. After removal of the outliers, intra- and inter-labo-
ratory mean %RSD of migration times and %Area were determined
for all peaks0 .1%; intra-laboratorymean total signal was evaluated
for each data set as well. Participant names were letter coded to
“blind” the results; for cases in which more than one laboratory from
a single organization participated, they were listed separately.
Statistical Data Evaluation and Outlier Analysis
Statistical (repeatability and reproducibility) and outlier anal-
yses were performed based on ISO 5725–2 guide7 principles.
Intra-laboratory analysis (repeatability) was assessed for relative
peak area, absolute peak area and total peak area for each site;
inter-laboratory analysis (reproducibility) was assessed for relative
peak area only because it is expected that absolute and total peak
areas would likely vary widely due to differences related to the
fluorescence detectors between sites. All of the data received from
the participating laboratories were critically examined for outlier
identification: i) outlying laboratories, which deviate in precision
(repeatability) indicating laboratory bias; ii) outlying results from
individual laboratories at a given level that deviate either in preci-
sion or in their mean value. From a statistical point of view,
unequal repeatability values deviate from a fundamental assump-
tion of analysis of variances (ANOVA), namely homogeneity of
variances. Too low or too high values lead to distributions that
are no longer normal. ISO recommends Mandel k and h statis-
tics, respectively, obtained as follows:
kij D sij
ffiffiffiffi
Pj
p
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiXP
iD 1s
2
ij
q (Eq:1)
and
hij D
yij ¡ yjffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1
Pj ¡ 1
X​ Pj
iD 1
.yij ¡ yj/2
r (Eq:2)
The statistic kij is a within-laboratory consistency evaluation
comparing the standard deviation of the percent peak area value
for a selected peak j within one laboratory i to the mean standard
deviation for the different laboratories for peak j, iD1 to p, where
p is the total number of laboratories and sij is the standard devia-
tion from replicates for one sample within one laboratory.
The statistic hij is a between-laboratory consistency statistic
that measures for a selected peak j the standardized version of the
mean value of the percent peak area value obtained by laboratory
i yij from the grand mean for that peak yj. This statistic provides
a measure for any laboratory bias. The above obtained ki and hi
values for the different peaks can be grouped per company and
plotted with the critical values of k and h statistics at the signifi-
cance level of 1% and 5%, explained in the ISO guideline 5725–
2. Mandel’s k and h values are only used as a graphical consis-
tency technique and not to suggest outlier removal.
Test for homogeneity of variances: Cochran’s test was imple-
mented as a numerical technique to recognize outliers and/or
stragglers in within-company variances. This test is calculated as:
CD s
2
maxXP
iD 1s
2
i
(Eq:3)
where s2max and s
2
i are the highest variance in the set and the variance
from laboratory i, respectively. Outlier rejection criteria were taken
from the ISO 5725–2 guideline, as well as critical C values. Varian-
ces significant at a D 0.01 (99% range) were considered as outliers
and removed from the data set. Stragglers (values significant at a D
0.05, 95% range) on the other hand were kept in for further
evaluations.
Test for outlying company means: Average of the results for
the same level obtained by the companies were tested for outliers
by the Grubb’s tests where the single outlier test was applied
meaning that it was investigated if there was one average, which
was too high or too low, compared to the others:
Gmin D Y ¡ Ymin
 
=s (Eq:4)
and
Gmax D Ymax ¡ Y
 
=s (Eq:5)
with Ymin the smallest mean laboratory value, Ymax the largest
mean laboratory value, Y the grand mean of all laboratories
and s the standard deviation on all mean laboratory values. The
absolute value of G is compared to the critical values for this test.
A value larger than the critical value for the Grubb’s test is con-
sidered an outlier.
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